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MINIREVIEWS

Ambulatory pulmonary artery pressure monitoring in
advanced heart failure patients
Srikanth Yandrapalli, Anoshia Raza, Sohaib Tariq, Wilbert S Aronow

Abstract

Srikanth Yandrapalli, Anoshia Raza, Sohaib Tariq, Wilbert S
Aronow, Department of Cardiology, New York Medical College
at Westchester Medical Center, Valhalla, NY 10595, United
States

Heart failure (HF) is an emerging epidemic associate
with significant morbidity, mortality, and health care
expenditure. Although there were major advances
in pharmacologic and device based therapies for
the management of HF, mortality of this condition
remains high. Accurate monitoring of HF patients for
exacerbations is very important to reduce recurrent
hospitalizations and its associated complications.
With the failure of clinical signs, tele-monitoring, and
laboratory bio-markers to function as early markers of
HF exacerbations, more sophisticated techniques were
sought to accurately predict the circulatory status in
HF patients in order to execute timely pharmacological
intervention to reduce frequent hospitalizations.
TM
CardioMEMS (St. Jude Medical, Inc., Saint Paul,
Minnesota) is an implantable, wireless pulmonary arterial
pressure (PAP) monitoring system which transmits the
patient’s continuous PAPs to the treating health care
provider in the ambulatory setting. PAP-guided medical
therapy modification has been shown to significantly
reduce HF-related hospitalization and overall mortality. In
advanced stages of HF, wireless access to hemodynamic
information correlated with earlier left ventricular assist
device implantation and shorter time to heart trans
plantation.
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Core tip: Traditional heart failure monitoring methods
have failed to accurately and timely identify worsening
heart failure. Remote pulmonary artery pressure
TM
monitoring via CardioMEMS heart failure system
identified heart failure exacerbations earlier and more
accurately than clinical signs, and timely medical
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interventions resulted in reduced hospitalizations and
mortality. Remote pulmonary artery pressure monitoring
appears to have positive clinical implications in patients
with mechanical circulatory support.

PREVIOUSLY TESTED METHODS FOR
MONITORING HF PATIENTS
Identification of physical manifestations such as weight
gain, extremity edema, fatigue, shortness of breath,
orthopnea, paroxysmal nocturnal dyspnea, jugular
venous distention, third heart sounds, and rales, etc.
have poor to moderate sensitivities and are often late
manifestations of worsening HF, thereby, relying on
these markers have limited impact on reducing HF
[6]
hospitalizations . Also, such efforts largely employ
patient self-management strategies, including diuretic
dose adjustments based on clinical worsening, and are
unsuccessful in patients with poor self-care skills and
[6]
compliance . Two large trials which investigated the
benefits of tele-monitoring in HF population failed to
show any significant decrease in the all-cause mortality
[6]
and HF hospitalizations in the tele-monitored group . A
smart-phone based electrocardiographic monitoring of
HF has been recently proposed, but there is not much
[7]
data exploring this idea .
[8]
Lainchbury et al compared N-terminal pro-Btype natriuretic (NT-proBNP) guided titration of medical
therapy in HF patients with intensive clinical manage
ment and with usual care in a randomized sample of 564
patients. There was a reduction in the 3-year mortality
in the NT-proBNP-guided group compared to the
clinically-guided group (30.9%; P = 0.048) and to those
with usual care (31.3%; P = 0.021). These benefits
were selectively seen in patients ≤ 75 years of age.
However, there was no statistically significant difference
in the overall hospitalizations for HF and the secondary
[8]
outcomes among all the groups . Another study
monitored plasma B-type natriuretic peptide (BNP) levels
in up to 558 chronic stable HF patients in an ambulatory
[9]
setting to predict imminent decompensation . The
study showed that both symptomatic and asymptomatic
HF patients had a wide range of plasma BNP levels.
Interestingly, 21% of symptomatic decompensated HF
patients had BNP levels below the diagnostic threshold
[9]
of < 100 pg/mL .
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INTRODUCTION
Heart failure (HF) is a chronic debilitating condition
which impairs the ability of the heart to effectively pump
the blood to the body to meet its metabolic require
ments. HF is an emerging epidemic with an estimated
prevalence of 5.8 million in the United States, and
[1]
over 23 million worldwide . Within the United States,
the incidence of HF exceeds 650000 each year with
an estimated annual financial burden of around 30.7
[2,3]
billion dollars . Although there were major advances
in pharmacologic and device based therapies for the
management of HF which improved the overall survival
over time, mortality of this condition remains high. The
estimated survival after the diagnosis of HF is 50% at 5
[1]
years and 10% at 10 years . Hospitalization for acute
decompensated HF serves as a poor prognostic indicator
with an approximate 30% and 50% readmission rates
[1,3]
at 1-mo and 6-mo, respectively . With improved
survival of patients after acute myocardial infarction, a
growing elderly population, and frequent hospitalizations
in the HF population owing to acute exacerbations, HF
continuous to be one of the leading causes of morbidity,
mortality, and health care expenditures in the United
States and worldwide.
Around 150000-250000 Americans suffer from
[4]
advanced stage HF . Although cardiac transplantation
is the gold standard treatment in such patients,
limited organ availability restricts the number of heart
transplants to around 2500 per year (https://www.unos.
org/data/transplant-trends/#transplants_by_organ).
More than 4000 patients are currently on the waiting
list for a cardiac transplant (www.unos.org/data/
transplant-trends/#waitlists_by_organ), a number
which is expected to increase significantly because of
the increasing number of patients living with advanced
HF and an increasing elderly population. Left ventricle
assist device (LVAD) has emerged as a life-saving
option for these patients as either bridge to transplant,
bridge to decision, bridge to recovery or as destination
therapy. Around 15000 HF patients across the world
[5]
are currently supported with LVADs . LVAD serves as
destination therapy in more than 45% of the patients
[5]
living with the device .

WJC|www.wjgnet.com

REMOTE HEMODYNAMIC MONITORING
IN HF PATIENTS
With the failure of reliable clinical symptoms/signs, telemonitoring, and laboratory bio-markers to help reduce
the hospitalizations, and health care expenditure in the
HF population, more sophisticated techniques were
sought to accurately predict the circulatory status in
HF patients in order to execute timely pharmacological
intervention to prevent the primary onus of this disease,
i.e., hospitalizations. Echocardiography is being used as
a monitoring system in the hospitalized and ambulatory
population, but it is associated with significant costs,
less accuracy, and observer variability. Traditionally,
in hospitalized HF patients, right heart catheterization
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(RHC) provides invaluable information regarding the
volume status and filling pressures which can form the
basis of successful medical management. However, RHC
is not routinely recommended to aid in the management
of hospitalized decompensated HF patients owing to
its invasive nature and associated risks. We had no
such accurate monitoring systems in the ambulatory
setting until scientific advances led to the development
of implantable hemodynamic monitors (IHMs) which
provided hemodynamic information comparable to the
[10]
information obtained from a RHC . The idea of IHM
based monitoring and necessary interventions in HF
patients was innovative and exiting.
Earlier trials of implantable hemodynamic monitoring
in HF patients did not show significant clinical benefit
or were unable to adequately assess clinical efficacy.
The COMPASS-HF (Chronicle Offers Management to
Patients with Advanced Signs and Symptoms of Heart
Failure) trial using Chronicle (Medtronic Inc., Minneapolis,
Minnesota) to estimate right ventricular pressures
and guide medical therapy, did not show a significant
reduction in HF-related events when compared to the
[11]
control group . The Reducing Decompensation Events
Utilizing Intracardiac Pressures in Patients With Chronic
Heart Failure (REDUCEhf) study employed a device
combining IHM and implantable cardioverter-defibrillator
technology to measure right ventricular pressures and
[12]
guide medical therapy . The REDUCEhf study was
unable to test clinical efficacy end points adequately and
findings from this study did not show a difference in the
rate of HF-equivalents when medical therapy was guided
[12]
based on the information obtained from the IHM .
The Hemodynamically Guided Home Self-Therapy
in Severe Heart Failure Patients (HOMEOSTASIS) trial
is a small study of 40 patients in which the benefit of
physician-directed patient self-management of left atrial
pressures as measured with the implantable HeartPOD
(St. Jude Medical Inc, Minneapolis, Minnesota) was inves
[13]
tigated . Left atrial pressure guided medical therapy
was associated with an improved event-free survival
(death or hospitalization for acute decompensated
HF), reduced mean daily left atrial pressures, improved
New York Heart Association (NYHA) functional class,
improved left ventricular ejection fraction, increased
doses of neuro-hormonal antagonists, and reduced
[13]
diuretic doses . Encouraging results from this smaller
study formed the basis of the larger and currently
ongoing LAPTOP-HF trial which will investigate the role of
implantable left atrial pressure monitoring in conjunction
with a new HF treatment paradigm across the spectrum
[14]
of HF patients .

pressure monitoring system. It measures PA pressures
from a battery free capacitive electromechanical
sensor which is permanently implanted with a delivery
system in the distal pulmonary artery with a RHC via
transvenous access. An electronic system transmits the
generated data to a secure network where it is readily
available for interpretation by the treating clinician.
[15]
Verdejo et al showed that wireless PA pressure moni
toring using the CardioMEMS sensor correlated with
Swan-Ganz catheter and echocardiographic PA pressure
measurements. The outcomes of remote management
of HF patients guided by wireless PA pressure moni
toring was investigated in the landmark CHAMPION
(CardioMEMS Heart Sensor Allows Monitoring of Pres
sure to Improve Outcomes in NYHA Class III Heart Fai
[16]
lure Patients) trial .
The CHAMPION trial is a randomized, controlled,
multi-center, single-blind trial in which 550 NYHA
class III HF patients were implanted with the wireless
[16]
CardioMEMS HF pressure sensor system . Physicians
had access to the PA pressures of the patients in the
treatment group only, in which medications were adjust
ed based on the generated data. The control group
received traditional HF management. The primary
efficacy endpoint was the rate of HF-related hospitali
zations at 6 mo. In comparison to the control group,
there was a remarkable 28% reduction in HF-related
hospitalizations at 6 mo, and 37% at 15 mo in the
[17]
treatment group (Hazard ratio 0.63, P < 0.0001) .
There were no pressure sensor failures and 98.6% of
the study population was free from device-related or
[17]
system-related complications . A sub-analysis of the
original trial in HF with preserved ejection fraction (HFpEF)
patients showed that there was a 50% reduction (P
< 0.0001) in HF-related hospitalizations at 17 mo in
[18]
the treatment group . These landmark findings led
to the Food and Drug Administration approval of the
TM
CardioMEMS HF system for ambulatory hemodynamic
monitoring in NYHA class III HF with reduced ejection
fraction (HFrEF) and HFpEF patients, who are on optimal
medical therapy, and had a HF hospitalization in the
[19]
previous year . In the 2016 European society of
Cardiology guidelines, CardioMEMS received a Class IIb
recommendation for directed therapy management and
[20]
monitoring tool in HF patients .
Numerous sub-analyses supported the encouraging
results obtained from the original CHAMPION trial. The
reduced HF-related hospitalization rate was postulated
to be from physician controlled effective changes in
diuretic dosing in the treatment group (P < 0.0001 for
more frequent diuretic dose changes in treatment group
[21]
compared to control) . Wireless PA pressure-guided
HF management was superior to clinical signs-guided
management with a 67% relative risk reduction (P =
0.0007) in HF hospitalizations when diuretic doses were
adjusted based on PA pressure alone vs clinical signs
[22]
alone . At 6 mo, the target group experienced a higher
frequency of medication adjustments with significant
increases in the doses of diuretics, vasodilators, and

CARDIOMEMSTM AND REMOTE
PULMONARY ARTERIAL PRESSURE
MONITORING
TM

CardioMEMS (St. Jude Medical, Inc., Saint Paul,
Minnesota) is a wireless pulmonary arterial (PA)
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[30]

neuro-hormonal antagonists with preserved renal
[23]
function despite intensification of diuretic therapy .
Remote PA pressure-guided treatment resulted in similar
reductions in HF hospitalization in HFrEF patients with
and without a cardiac resynchronization therapy (CRT)
device, suggesting that HF management guided by PA
[24]
pressures may provide additive benefits to CRT .
Wireless PA-pressure monitoring on top of guidelinedirected medical therapy and CRT or ICD, had an
additive effect in improving HF hospitalizations and
[25]
mortality . There were significant reductions in allcause hospitalization (P < 0.0032), and in the number
of deaths or all-cause hospitalization in the treatment
[26]
group (P = 0.0017) . Interestingly, it was observed
that measurement of PA pressures using RHC alone
may result in under-diagnosing pulmonary hypertension
related to HF. Of the 217 patients who did not meet
criteria for pulmonary hypertension during implantation
RHC, 49% met criteria for pulmonary hypertension
[27]
[28]
based in the first week IHM data . Alam et al
compared 34 HF patients who had an implanted Cardio
MEMS HF system with 32 HF patients without an IHM,
and reported a three-fold improvement in the Kansas
City Cardiomyopathy Questionnaire scores (P < 0.001)
and increased 6-min walk distance (P < 0.001) in the
CardioMEMS group. These findings represent improved
quality of life and exercise capacity. Results from the
CHAMPION trial and subsequent sub-analysis confirmed
that early and appropriate medical interventions follo
wing early detection of elevated PA pressures resulted
in a significant reduction of HF-related hospitalizations,
readmission rates and mortality.
There is an increasing trend in the number of HF
patients living with LVADs and an increasing use of
LVAD as destination therapy for advanced HF patients.
[29]
Feldman et al
conducted a sub-analysis of the
CHAMPION trial to determine the validity of remote PA
pressure directed therapy on optimization of medications,
pump parameters, and timing of heart transplantation
in patients receiving a LVAD. Of the 27 patients who
received an LVAD, 15 patients were assigned to the
treatment group where their medical therapy was
modified based on PA pressures and 12 patients in the
control group received standard care. The data obtained
from CardioMEMS HF system led to significantly more
medication changes in the treatment arm (P = 0.025).
Wireless access to hemodynamic information correlated
with earlier LVAD implantation (P = 0.001) and shorter
time to transplantation (P = 0.001) in the treatment
[29]
arm .
Over the last few decades, efforts have been directed
at reducing recurrent hospitalizations for worsening HF
in this patient population. A variety of markers varying
from clinical symptoms and signs to laboratory testing
have been investigated to identify acute decompensated
HF early enough to prevent hospitalizations, subsequent
morbidity, and health care expenditure. Daily weight
monitoring is a cornerstone for managing HF patients. It
has been shown that increases in body weight begin at
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least 1 week before a HF hospitalization . However, less
than a half of the HF patients including those recently
discharged after a hospitalization for HF exacerbation
[31]
check their weight on a daily basis . Daily electronic
body weight transmission to a HF clinic in patients with
severe HF who had a recent HF hospitalization did not
show any benefit in reducing HF re-hospitalization or
[32]
death .

CONCLUSION
HF continues to be a major public health problem with
a significant financial burden. As more and more peo
ple are living with HF, it is important have a simple,
reliable, and valid monitoring system to aid in the early
identification and appropriate management of worsening
HF in the ambulatory setting. IHM is an innovative
and exciting monitoring system for HF management.
CardioMEMS has steered HF research into a new direction
which will serve as the gateway to future therapies and
innovations in the management of chronic HF patients.
Also with increasing number of people living with LVADs
and LVAD being used as destination therapy in a large
percentage of the LVAD population, CardioMEMS will be
a promising monitoring system to better manage HF
as well as the LVAD device in this population. However,
given the small number of participants involved in many
of the available trials, large multicenter randomized
clinical trials are needed to make valid recommendations
in an effort to lower mortality and improve quality of life
in the chronically sick HF population. Wireless left atrial
pressure-guided and PA pressure-guided management
of HF can have a substantial positive effect on reducing
the financial burden of HF and improving the overall
morbidity and mortality in this population.
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